• 1. An ionic liquid-mesoporous silica blend as a novel adsorbent for the adsorption and recovery of palladium ions, and its applications in continuous flow study and as an industrial catalyst?
  Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678
• 2. Achieving Efficient Uranium Extraction by In-situ Ultrasonic Texturization of Commercial Fe Powder
  BomingZhu,HongweiWu,JieKang,XiaofangYu,TaoChen,RuCheng,GuolinYang,WencaiBai,WenkunZhu,RongHe
• 3. An automated in-chip-catalytic–spectrophotometric method for determination of copper(ii) using a multisyringe flow injection analysis-multipumping flow system?
  Camelia Henríquez,Edwin Palacio,Víctor Cerdà Anal. Methods, 2014,6, 8494-8504
• 4. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 5. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines N-alkylpyrrolidines

Introduction to (1-Methylpyrrolidin-3-yl)methanamine (CAS No. 13005-11-3)

(1-Methylpyrrolidin-3-yl)methanamine, also known by its CAS number 13005-11-3, is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a pyrrolidine ring and a methylated amine group. These properties make it an attractive candidate for various applications, particularly in the development of new therapeutic agents.

The chemical structure of (1-Methylpyrrolidin-3-yl)methanamine consists of a five-membered pyrrolidine ring with a methyl group attached to one of the nitrogen atoms and a methylene bridge connecting the ring to an amine group. This configuration imparts specific chemical and biological properties that have been extensively studied in recent years. The compound's ability to interact with various biological targets, such as receptors and enzymes, has made it a focal point in drug discovery and development.

Recent research has highlighted the potential of (1-Methylpyrrolidin-3-yl)methanamine in several therapeutic areas. For instance, studies have shown that this compound can modulate the activity of certain neurotransmitter systems, making it a promising lead for the treatment of neurological disorders. Additionally, its ability to cross the blood-brain barrier (BBB) efficiently has further enhanced its appeal as a potential drug candidate.

In the realm of medicinal chemistry, (1-Methylpyrrolidin-3-yl)methanamine has been used as a building block for the synthesis of more complex molecules. Its structural flexibility allows for the introduction of various functional groups, which can be tailored to optimize pharmacological properties such as potency, selectivity, and bioavailability. This versatility has led to the development of numerous derivatives that are currently being evaluated in preclinical and clinical trials.

One notable application of (1-Methylpyrrolidin-3-yl)methanamine is in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Research has demonstrated that this compound can enhance cognitive function and improve motor skills in animal models. These findings have paved the way for further investigation into its potential as a therapeutic agent for these debilitating conditions.

Beyond its therapeutic applications, (1-Methylpyrrolidin-3-yl)methanamine has also been explored for its use in diagnostic imaging. Its ability to bind to specific receptors in the brain makes it a valuable tool for visualizing neural activity and identifying disease biomarkers. This dual functionality—therapeutic and diagnostic—has sparked interest among researchers and clinicians alike.

In terms of safety and toxicity, studies have generally shown that (1-Methylpyrrolidin-3-yl)methanamine is well-tolerated at therapeutic doses. However, like any chemical compound, it is essential to conduct thorough safety assessments before advancing to clinical trials. Preclinical studies have demonstrated that this compound does not exhibit significant cytotoxicity or genotoxicity at relevant concentrations.

The synthesis of (1-Methylpyrrolidin-3-yl)methanamine involves several well-established chemical reactions, including reductive amination and ring formation. These processes can be optimized to achieve high yields and purity levels, making it feasible for large-scale production. The availability of efficient synthetic routes has facilitated its use in both academic research and industrial applications.

In conclusion, (1-Methylpyrrolidin-3-yl)methanamine (CAS No. 13005-11-3) is a multifaceted compound with significant potential in various areas of medicinal chemistry and pharmaceutical research. Its unique structural features, coupled with its biological activity and safety profile, make it an attractive candidate for further exploration and development. As research continues to uncover new applications and optimize its properties, this compound is poised to play an increasingly important role in advancing healthcare solutions.

• 959239-12-4(1-(1-propylpyrrolidin-3-yl)methanamine)
• 51388-01-3((1-Ethylpyrrolidin-3-yl)methylamine)
• 1313738-92-9(N,N-Dimethyl(1-methylpyrrolidin-3-yl)methanamine)
• 99724-17-1(dimethyl[(pyrrolidin-3-yl)methyl]amine)
• 869188-25-0(2-ethyl-octahydropyrrolo3,4-cpyrrole)
• 86732-28-7(2-methyloctahydropyrrolo[3,4-c]pyrrole)
• 763065-29-8(Pyrrolidine,1-[(3S)-3-pyrrolidinylmethyl]- (9CI))
• 959239-24-8(N-(1-methylpyrrolidin-3-yl)methylethanamine)
• 741288-65-3(dimethyl({[(3S)-pyrrolidin-3-yl]methyl})amine)
• 884504-74-9(1-(1-Ethylpyrrolidin-3-yl)-N-methylmethanamine)